A049180 Stock Overview
A biotechnology company, provides bone graft materials, medical devices, and cosmeceuticals in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
Cellumed Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩1,020.00 |
| 52 Week High | ₩4,415.00 |
| 52 Week Low | ₩965.00 |
| Beta | 1.13 |
| 1 Month Change | -13.92% |
| 3 Month Change | -54.67% |
| 1 Year Change | -37.23% |
| 3 Year Change | -82.50% |
| 5 Year Change | n/a |
| Change since IPO | -90.33% |
Recent News & Updates
Little Excitement Around Cellumed Co.,Ltd.'s (KOSDAQ:049180) Revenues As Shares Take 26% Pounding
Apr 13
Revenues Working Against Cellumed Co.,Ltd.'s (KOSDAQ:049180) Share Price
Feb 20Recent updates
Little Excitement Around Cellumed Co.,Ltd.'s (KOSDAQ:049180) Revenues As Shares Take 26% Pounding
Apr 13Revenues Working Against Cellumed Co.,Ltd.'s (KOSDAQ:049180) Share Price
Feb 20Benign Growth For Cellumed Co.,Ltd. (KOSDAQ:049180) Underpins Stock's 35% Plummet
Nov 01Cellumed Co.,Ltd.'s (KOSDAQ:049180) Low P/S No Reason For Excitement
Aug 27CellumedLtd (KOSDAQ:049180) Has Debt But No Earnings; Should You Worry?
Jun 04Shareholder Returns
| A049180 | KR Medical Equipment | KR Market | |
|---|---|---|---|
| 7D | -4.2% | 3.8% | 2.2% |
| 1Y | -37.2% | -22.4% | -6.5% |
Return vs Industry: A049180 underperformed the KR Medical Equipment industry which returned -21.2% over the past year.
Return vs Market: A049180 underperformed the KR Market which returned -8.6% over the past year.
Price Volatility
| A049180 volatility | |
|---|---|
| A049180 Average Weekly Movement | 8.2% |
| Medical Equipment Industry Average Movement | 6.5% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in KR Market | 12.6% |
| 10% least volatile stocks in KR Market | 2.9% |
Stable Share Price: A049180 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A049180's weekly volatility has decreased from 14% to 8% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1985 | 89 | In-soo Yoo | www.cellumed.co.kr |
Cellumed Co.,Ltd., a biotechnology company, provides bone graft materials, medical devices, and cosmeceuticals in South Korea. The company offers CLnZyme, a mRNA enzyme; cosmeceuticals, such as FGF7 for skin regeneration and TGFß-1 for tissue regeneration; and electric motorcycles. It provides tissue bank products, such as celluderm powder, ultra, and HD implant for the skin; patellar tendon hemi whole, posterior tibialis, anterior tibialis, semitendinosus, gracilis, and peroneus longus tendons, and meniscus lateral and medial; cancellous bone chips and cortical cancellous dental bone powders; and femoral, tibia, radius, and ulna shafts, femur distal, tibia proximal, and cervical spacer bones.
Cellumed Co.,Ltd. Fundamentals Summary
| A049180 fundamental statistics | |
|---|---|
| Market cap | ₩52.54b |
| Earnings (TTM) | -₩31.55b |
| Revenue (TTM) | ₩129.14b |
0.4x
P/S Ratio-1.7x
P/E RatioIs A049180 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A049180 income statement (TTM) | |
|---|---|
| Revenue | ₩129.14b |
| Cost of Revenue | ₩119.71b |
| Gross Profit | ₩9.43b |
| Other Expenses | ₩40.97b |
| Earnings | -₩31.55b |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -612.45 |
| Gross Margin | 7.30% |
| Net Profit Margin | -24.43% |
| Debt/Equity Ratio | 96.8% |
How did A049180 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/18 09:41 |
| End of Day Share Price | 2025/04/18 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cellumed Co.,Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.